Macular degeneration classification: Difference between revisions
(Created page with "__NOTOC__ {{Macular degeneration}} {{CMG}} ==Classification== ===Age-related Macular Degeneration=== Age-related macular degeneration begins with characteristic yellow deposi...") |
m (Bot: Removing from Primary care) |
||
| (2 intermediate revisions by one other user not shown) | |||
| Line 5: | Line 5: | ||
==Classification== | ==Classification== | ||
===Age-related Macular Degeneration=== | ===Age-related Macular Degeneration=== | ||
Age-related macular degeneration begins with characteristic yellow deposits in the macula (central area of the retina which provides detailed central vision) called [[drusen]] between the [[retinal pigment epithelium]] and the underlying [[choroid]]. Most people with these early changes (referred to as age-related maculopathy) have good vision. | Age-related macular degeneration begins with characteristic yellow deposits in the macula (central area of the [[retina]] which provides detailed central vision) called [[drusen]] between the [[retinal pigment epithelium]] and the underlying [[choroid]]. Most people with these early changes (referred to as age-related maculopathy) have good vision. People with [[drusen]] can go on to develop advanced AMD. The risk is considerably higher when the drusen are large and numerous and associated with disturbance in the pigmented cell layer under the [[macula]]. Recent research suggests that large and soft drusen are related to elevated [[cholesterol]] deposits and may respond to cholesterol lowering agents or the Rheo Procedure. | ||
Advanced AMD, which is responsible for profound vision loss, has two forms: dry and wet. Central geographic atrophy, the dry form of advanced AMD, results from atrophy to the retinal pigment epithelial layer below the retina, which causes vision loss through loss of | Advanced AMD, which is responsible for profound vision loss, has two forms: dry and wet. Central geographic atrophy, the dry form of advanced AMD, results from atrophy to the retinal pigment epithelial layer below the [[retina]], which causes vision loss through loss of [[photoreceptor]]s (rods and cones) in the central part of the eye. While no treatment is available for this condition, vitamin supplements with high doses of antioxidants, [[lutein]] and [[zeaxanthin]], have been demonstrated by the National Eye Institute and others to slow the progression of dry macular degeneration and in some patients, improve visual acuity. | ||
[[Neovascular]] or [[exudative]] AMD, the wet form of advanced AMD, causes vision loss due to abnormal blood vessel growth in the choriocapillaries, through [[Bruch's membrane]], ultimately leading to blood and protein leakage below the macula. | [[Neovascular]] or [[exudative]] AMD, the wet form of advanced AMD, causes vision loss due to abnormal blood vessel growth in the choriocapillaries, through [[Bruch's membrane]], ultimately leading to blood and protein leakage below the macula. Bleeding, leaking, and scarring from these blood vessels eventually cause irreversible damage to the photoreceptors and rapid vision loss if left untreated. | ||
Until recently, no effective treatments were known for wet macular degeneration. However, new drugs, called [[anti-angiogenics]] or anti-VEGF (anti-[[Vascular Endothelial Growth Factor]]) agents, when injected directly into the vitreous humor of the eye using a small, painless needle, can cause regression of the abnormal blood vessels and improvement of vision. The injections frequently have to be repeated on a monthly or bi-monthly basis. Examples of these agents include [[Lucentis]], [[Avastin]] and [[Macugen]]. Only Lucentis and Macugen are FDA approved as of April 2007. | Until recently, no effective treatments were known for wet macular degeneration. However, new drugs, called [[anti-angiogenics]] or anti-VEGF (anti-[[Vascular Endothelial Growth Factor]]) agents, when injected directly into the vitreous humor of the eye using a small, painless needle, can cause regression of the abnormal blood vessels and improvement of vision. The injections frequently have to be repeated on a monthly or bi-monthly basis. Examples of these agents include [[Lucentis]], [[Avastin]], and [[Macugen]]. Only Lucentis and Macugen are FDA approved as of April 2007. Macugen has been found to have only minimal benefits in neovascular AMD and is no longer used. Worldwide, Avastin has been used extensively, with excellent results, despite its "off label" status. [[Genentech]], the maker of both Avastin and Lucentis, has been hoping to promote the use of Lucentis due to the potential for much higher revenues. The cost of Lucentis is approximately 2000 USD while the cost of Avastin is approximately 50 USD. Fortunately, retinal specialists worldwide have together proven that Avastin is at least as effective and safe as Lucentis, at a fraction of the cost. | ||
===Juvenile Macular Degeneration=== | ===Juvenile Macular Degeneration=== | ||
Juvenile macular degeneration is not a term in standard usage at this time. The preferred term for conditions that affect the macula in younger individuals related to genetics is macular dystrophy. | Juvenile macular degeneration is not a term in standard usage at this time. The preferred term for conditions that affect the macula in younger individuals related to genetics is macular dystrophy. Examples of these include: | ||
*[[Best's disease]] | *[[Best's disease]] | ||
*Doyne's honeycomb retinal dystrophy | *Doyne's honeycomb retinal dystrophy | ||
| Line 20: | Line 20: | ||
The first genetic link to juvenile macular degeneration was discovered at the [[Cleveland Clinic]]. | The first genetic link to juvenile macular degeneration was discovered at the [[Cleveland Clinic]]. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Optometry]] | [[Category:Optometry]] | ||
[[Category:Ophthalmology]] | [[Category:Ophthalmology]] | ||
| Line 31: | Line 33: | ||
[[Category:Aging-associated diseases]] | [[Category:Aging-associated diseases]] | ||
[[Category:Blindness]] | [[Category:Blindness]] | ||
[[Category:Needs overview]] | [[Category:Needs overview]] | ||
Latest revision as of 22:36, 29 July 2020
|
Macular degeneration Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Macular degeneration classification On the Web |
|
American Roentgen Ray Society Images of Macular degeneration classification |
|
Risk calculators and risk factors for Macular degeneration classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Classification
Age-related macular degeneration begins with characteristic yellow deposits in the macula (central area of the retina which provides detailed central vision) called drusen between the retinal pigment epithelium and the underlying choroid. Most people with these early changes (referred to as age-related maculopathy) have good vision. People with drusen can go on to develop advanced AMD. The risk is considerably higher when the drusen are large and numerous and associated with disturbance in the pigmented cell layer under the macula. Recent research suggests that large and soft drusen are related to elevated cholesterol deposits and may respond to cholesterol lowering agents or the Rheo Procedure.
Advanced AMD, which is responsible for profound vision loss, has two forms: dry and wet. Central geographic atrophy, the dry form of advanced AMD, results from atrophy to the retinal pigment epithelial layer below the retina, which causes vision loss through loss of photoreceptors (rods and cones) in the central part of the eye. While no treatment is available for this condition, vitamin supplements with high doses of antioxidants, lutein and zeaxanthin, have been demonstrated by the National Eye Institute and others to slow the progression of dry macular degeneration and in some patients, improve visual acuity.
Neovascular or exudative AMD, the wet form of advanced AMD, causes vision loss due to abnormal blood vessel growth in the choriocapillaries, through Bruch's membrane, ultimately leading to blood and protein leakage below the macula. Bleeding, leaking, and scarring from these blood vessels eventually cause irreversible damage to the photoreceptors and rapid vision loss if left untreated.
Until recently, no effective treatments were known for wet macular degeneration. However, new drugs, called anti-angiogenics or anti-VEGF (anti-Vascular Endothelial Growth Factor) agents, when injected directly into the vitreous humor of the eye using a small, painless needle, can cause regression of the abnormal blood vessels and improvement of vision. The injections frequently have to be repeated on a monthly or bi-monthly basis. Examples of these agents include Lucentis, Avastin, and Macugen. Only Lucentis and Macugen are FDA approved as of April 2007. Macugen has been found to have only minimal benefits in neovascular AMD and is no longer used. Worldwide, Avastin has been used extensively, with excellent results, despite its "off label" status. Genentech, the maker of both Avastin and Lucentis, has been hoping to promote the use of Lucentis due to the potential for much higher revenues. The cost of Lucentis is approximately 2000 USD while the cost of Avastin is approximately 50 USD. Fortunately, retinal specialists worldwide have together proven that Avastin is at least as effective and safe as Lucentis, at a fraction of the cost.
Juvenile Macular Degeneration
Juvenile macular degeneration is not a term in standard usage at this time. The preferred term for conditions that affect the macula in younger individuals related to genetics is macular dystrophy. Examples of these include:
- Best's disease
- Doyne's honeycomb retinal dystrophy
- Sorsby's disease
- Stargardt's disease
The first genetic link to juvenile macular degeneration was discovered at the Cleveland Clinic.